BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
The last time I spoke about Praxis Precision Medicines, Inc. (NASDAQ:PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At ...
Praxis Precision Medicines Inc PRAX announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and multiple ascending doses (MAD) of PRAX-628.
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) ...
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Earnings call Praxis reported top-line results from its RADIANT study showing vimatrogene achieved a 56% median seizure reduction and 60% responder rate in refractory focal epilepsy patients, ...
A study investigating the functional connectivity of the praxis network in patients in the early stages of Parkinson’s disease (PD) found that dopaminergic therapy may normalize praxis abilities and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback